Passage Bio's Q2 2024 Financial Results and Business Progress
Thursday, 8 August 2024, 06:00
Passage Bio Reports Financial Progress
Passage Bio has shared its financial results for the second quarter of 2024, revealing both fiscal health and recent advancements in their clinical trials.
Key Highlights
- Enrollment of the first FTD-GRN patient in Cohort 2 of the upliFT-D trial.
- Planned presentation of updated safety and biomarker data from Cohort 1 FTD-GRN patients.
- Strong focus on advancing research and development initiatives.
Conclusion
With these significant milestones, Passage Bio shows a robust commitment to addressing neurological diseases, which is critical for their ongoing endeavors in the biotechnology sector.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.